Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Suzhou
Clinical trial register · China

Clinical Trials in Suzhou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19187 matching records held by the registry are in this view. Synced 09 Nov 2026, 03:17 UTC
19187
Studies in scope
all four open statuses
11790
Recruiting now
open to new participants
2028
Lead sponsors
across recruiting studies
Top sites
Beijing 68 Guangzhou 52 Wuhan 33 Shanghai 29 Nanjing 25
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
The First Affiliated Hospital of Soochow University115 Second Affiliated Hospital of Soochow University16 Capital Medical University9 Novartis Pharmaceuticals8 Takeda7 Clear sponsor filter
Site location
Beijing68 Guangzhou52 Wuhan33 Shanghai29 Nanjing25
All 63 locations
Target enrolment
to

Trials with a site in Suzhou

8 of 19187 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
A Study to Evaluate the Efficacy of NIO752 in Participants With Progressive Supranuclear Palsy
NCT07498426Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS)
Novartis Pharmaceuticals
Phase 3
300
Chengdu, Beijing, Jinan, Shanghai, Suzhou, Wuhan
2026-06-03
Recruiting
Novartis Pharmaceuticals
Phase 3
1,275
Guangzhou, Zunyi, Zhengzhou, Wuhan, Hohhot, Suzhou, Changchun, Shenyang
2025-11-11
Active, closed
Novartis Pharmaceuticals
Phase 3
146
Hefei, Guangzhou, Shenzhen, Shijiazhuang, Changsha, Suzhou, Xi'an, Xianyang
2024-07-31
Recruiting
Novartis Pharmaceuticals
Phase 3
550
Guangzhou, Shantou, Nanjing, Suzhou, Nanchang, Pingxiang, Changchun, Linyi
2024-05-21
Active, closed
Novartis Pharmaceuticals
Phase 3
436
Guangzhou, Shantou, Haikou, Zhuzhou, Nanjing, Suzhou, Nanchang, Pingxiang
2023-03-02
Active, closed
Novartis Pharmaceuticals
Phase 4
134
Chongqing, Shijiazhuang, Harbin, Changsha, Nanjing, Suzhou, Changchun, Kunming
2022-07-07
Active, closed
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
NCT04971226Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive
DrugsBosutinib·Asciminib·ABL001·Nilotinib
Novartis Pharmaceuticals
Phase 3
405
Guangzhou, Shenzhen, Zhengzhou, Wuhan, Nanjing, Suzhou, Xian, Chengdu
2021-10-06
Active, closed
Novartis Pharmaceuticals
Phase 3
5,101
Guangzhou, Shijiazhuang, Harbin, Zhengzhou, Wuhan, Nanjing, Suzhou, Changchun
2018-12-07
Rows per page Showing 1–8 of 8
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 9 November 2026. https://priyalifescience.com/clinical-trials-china/city/suzhou

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,187 studies in total at the last sync on 09 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 8 of those studies with a site in Suzhou that also match the filters currently applied.

How many clinical trials are recruiting in Suzhou?

3 of the 8 studies on this page are recruiting new participants as of the 09 Nov 2026, 03:17 UTC sync. A further 0 have not yet opened recruitment, 5 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Suzhou), 8 studies
PhaseStudiesRecruitingShare
Phase 37387.5%
Phase 41012.5%

Most active sponsors

Lead sponsors with the most studies (Suzhou)
Lead sponsorStudiesRecruiting
Novartis Pharmaceuticals83
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.